Tamoxifen

Generic Name
Tamoxifen
Brand Names
Soltamox
Drug Type
Small Molecule
Chemical Formula
C26H29NO
CAS Number
10540-29-1
Unique Ingredient Identifier
094ZI81Y45
Background

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...

Indication

Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions
Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
Associated Therapies
Ovulation induction therapy
Clinical Trials
Related News

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

First Posted Date
2016-07-06
Last Posted Date
2019-06-04
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
42
Registration Number
NCT02824224
Locations
🇺🇸

OHSU Center For Women's Health, Portland, Oregon, United States

Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country

Phase 2
Completed
Conditions
Breast Neoplasms
Breast Cancer
Interventions
Drug: Tamoxifen
First Posted Date
2016-06-20
Last Posted Date
2017-01-30
Lead Sponsor
Vanderbilt University
Target Recruit Count
35
Registration Number
NCT02806544

TAmoxifen Versus LIdocaine Cream. A Randomized Clinical Trial for Reducing Pain and Discomfort During Mammography

First Posted Date
2016-06-16
Last Posted Date
2018-05-04
Lead Sponsor
Universidade Federal de Goias
Target Recruit Count
450
Registration Number
NCT02801786
Locations
🇧🇷

Universidade Federal de Goias, Goiania, Goias, Brazil

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

First Posted Date
2016-05-06
Last Posted Date
2024-03-20
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
195
Registration Number
NCT02764541
Locations
🇺🇸

Stamford Hospital, Stamford, Connecticut, United States

🇺🇸

Dana-Farber at St. Elizabeth's Medical Center, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 8 locations

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

First Posted Date
2016-04-21
Last Posted Date
2024-06-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
234
Registration Number
NCT02747004
Locations
🇺🇸

The University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States

🇦🇷

Clinica Viedma, Viedma, Río Negro, Argentina

and more 56 locations

Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

First Posted Date
2016-04-05
Last Posted Date
2016-04-05
Lead Sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Target Recruit Count
241
Registration Number
NCT02728622

Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF

Phase 4
Conditions
Infertility
Interventions
Drug: Tamoxifen
Drug: Clomiphene
First Posted Date
2016-02-24
Last Posted Date
2016-02-25
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
210
Registration Number
NCT02690870

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

First Posted Date
2016-01-29
Last Posted Date
2024-07-29
Lead Sponsor
Oana Danciu, MD
Target Recruit Count
49
Registration Number
NCT02668666
Locations
🇺🇸

Penn State Cancer Institute, Hershey, Pennsylvania, United States

🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 4 locations

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

First Posted Date
2015-10-26
Last Posted Date
2022-01-21
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
7
Registration Number
NCT02586675
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Phase 2
Completed
Conditions
Ovarian Carcinoma
Interventions
Drug: Tamoxifen
Drug: Regorafenib
First Posted Date
2015-10-22
Last Posted Date
2023-09-06
Lead Sponsor
ARCAGY/ GINECO GROUP
Target Recruit Count
68
Registration Number
NCT02584465
Locations
🇫🇷

ORACLE - Centre d'Oncologie de Gentilly, Nancy, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Centre Catherine de Sienne, Nantes, France

and more 18 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy